🚀 VC round data is live in beta, check it out!
ANI Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for ANI Pharmaceuticals and similar public comparables like Semnur Pharmaceuticals, Taysha GTx, Palvella Therapeutics, Vericel and more.
ANI Pharmaceuticals Overview
About ANI Pharmaceuticals
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Founded
2001
HQ
Employees
897
Website
Sectors
Financials (LTM)
EV
$2B
ANI Pharmaceuticals Financials
ANI Pharmaceuticals reported last 12-month revenue of $944M and EBITDA of $246M.
In the same LTM period, ANI Pharmaceuticals generated $575M in gross profit, $246M in EBITDA, and $173M in net income.
Revenue (LTM)
ANI Pharmaceuticals P&L
In the most recent fiscal year, ANI Pharmaceuticals reported revenue of $883M and EBITDA of $230M.
ANI Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $944M | XXX | $883M | XXX | XXX | XXX |
| Gross Profit | $575M | XXX | $542M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $246M | XXX | $230M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| Net Profit | $173M | XXX | $162M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | — | — | $331M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ANI Pharmaceuticals Stock Performance
ANI Pharmaceuticals has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
ANI Pharmaceuticals' stock price is $80.95.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 3.7% | XXX | XXX | XXX | $7.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialANI Pharmaceuticals Valuation Multiples
ANI Pharmaceuticals trades at 2.3x EV/Revenue multiple, and 8.8x EV/EBITDA.
EV / Revenue (LTM)
ANI Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, ANI Pharmaceuticals has market cap of $2B and EV of $2B.
Equity research analysts estimate ANI Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ANI Pharmaceuticals has a P/E ratio of 10.7x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | 8.8x | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBIT | 8.8x | XXX | 9.5x | XXX | XXX | XXX |
| EV/Gross Profit | 3.8x | XXX | 4.0x | XXX | XXX | XXX |
| P/E | 10.7x | XXX | 11.4x | XXX | XXX | XXX |
| EV/FCF | 14.1x | XXX | 14.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ANI Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ANI Pharmaceuticals Margins & Growth Rates
ANI Pharmaceuticals' revenue in the last 12 month grew by 19%.
ANI Pharmaceuticals' revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.5M for the same period.
ANI Pharmaceuticals' rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ANI Pharmaceuticals' rule of X is 84% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
ANI Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 23% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 84% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ANI Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ANI Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Semnur Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Taysha GTx | XXX | XXX | XXX | XXX | XXX | XXX |
| Palvella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Vericel | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharvaris | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ANI Pharmaceuticals M&A Activity
ANI Pharmaceuticals acquired XXX companies to date.
Last acquisition by ANI Pharmaceuticals was on XXXXXXXX, XXXXX. ANI Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ANI Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialANI Pharmaceuticals Investment Activity
ANI Pharmaceuticals invested in XXX companies to date.
ANI Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. ANI Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ANI Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ANI Pharmaceuticals
| When was ANI Pharmaceuticals founded? | ANI Pharmaceuticals was founded in 2001. |
| Where is ANI Pharmaceuticals headquartered? | ANI Pharmaceuticals is headquartered in United States. |
| How many employees does ANI Pharmaceuticals have? | As of today, ANI Pharmaceuticals has over 897 employees. |
| Who is the CEO of ANI Pharmaceuticals? | ANI Pharmaceuticals' CEO is Nikhil Lalwani. |
| Is ANI Pharmaceuticals publicly listed? | Yes, ANI Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of ANI Pharmaceuticals? | ANI Pharmaceuticals trades under ANIP ticker. |
| When did ANI Pharmaceuticals go public? | ANI Pharmaceuticals went public in 1999. |
| Who are competitors of ANI Pharmaceuticals? | ANI Pharmaceuticals main competitors are Semnur Pharmaceuticals, Taysha GTx, Palvella Therapeutics, Vericel. |
| What is the current market cap of ANI Pharmaceuticals? | ANI Pharmaceuticals' current market cap is $2B. |
| What is the current revenue of ANI Pharmaceuticals? | ANI Pharmaceuticals' last 12 months revenue is $944M. |
| What is the current revenue growth of ANI Pharmaceuticals? | ANI Pharmaceuticals revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of ANI Pharmaceuticals? | Current revenue multiple of ANI Pharmaceuticals is 2.3x. |
| Is ANI Pharmaceuticals profitable? | Yes, ANI Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ANI Pharmaceuticals? | ANI Pharmaceuticals' last 12 months EBITDA is $246M. |
| What is ANI Pharmaceuticals' EBITDA margin? | ANI Pharmaceuticals' last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of ANI Pharmaceuticals? | Current EBITDA multiple of ANI Pharmaceuticals is 8.8x. |
| What is the current FCF of ANI Pharmaceuticals? | ANI Pharmaceuticals' last 12 months FCF is $153M. |
| What is ANI Pharmaceuticals' FCF margin? | ANI Pharmaceuticals' last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of ANI Pharmaceuticals? | Current FCF multiple of ANI Pharmaceuticals is 14.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.